Table 2.
Payment characteristics to psychiatrists by pharmaceutical company, 2016–2017 CMS Open Payments Data
| Manufacturer or GPO | Total payment (%) | 50th percentile payment | 90th percentile payment | Max payment | Number of payments | No. of psychiatrists | No. of psychiatrists receiving > $20,000 | No. of psychiatrists receiving > $100,000 | |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Otsuka America Pharmaceutical, Inc. | $20,446,829 (18.5) | 18.26 | 141.85 | $40,000 | 130,285 | 13,470 | 557 | 206 |
| 2 | Alkermes, Inc. | $14,871,564 (13.5) | 20.15 | 412.94 | $353,175 | 53,716 | 8,423 | 452 | 180 |
| 3 | Sunovion Pharmaceuticals, Inc. | $14,780,622 (13.4) | 13.40 | 101.44 | $ 64,142 | 147,763 | 11,815 | 551 | 206 |
| 4 | Allergan, Inc. | $13,929,387 (12.6) | 14.18 | 200.00 | $ 12,600 | 108,583 | 9,227 | 511 | 188 |
| 5 | Takeda Pharmaceuticals, Inc. | $10,599,055 (9.6) | 16.38 | 920.00 | $ 40,218 | 44,339 | 5,865 | 432 | 165 |
| 6 | Janssen Pharmaceuticals, Inc | $4,928,120 (4.5) | 16.23 | 95.77 | $ 10,130 | 56,945 | 7,968 | 370 | 140 |
| 7 | Merck Sharp & Dohme Corp. | $3,853,508 (3.5) | 15.51 | 584.62 | $ 70,000 | 17,954 | 4,032 | 319 | 124 |
| 8 | Shire North American Group, Inc. | $3,259,393 (2.9) | 15.45 | 24.89 | $ 20,000 | 49,120 | 6,523 | 361 | 117 |
| 9 | Avanir Pharmaceuticals, Inc. | $3,237,007 (2.9) | 21.39 | 1,400.00 | $ 50,000 | 10,042 | 2,051 | 237 | 97 |
| 10 | Acadia Pharmaceuticals, Inc. | $2,928,596 (2.7) | 45.36 | 2,300.00 | $ 11,500 | 6,271 | 1,579 | 172 | 81 |
| *Other companies | $17,678,525 (16.0) | 15.51 | 54.00 | $ 108,000 | 187,859 | 15,904 | 669 | 229 | |
| Total | $110,512,607 (100.0) | 15.87 | 124.19 | $ 353,175 | 812,877 | 26,422 | 741 | 253 | |
Note:
*
Includes data from over 350 different pharmaceutical or medical device manufacturing companies.